Related references
Note: Only part of the references are listed.The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft
Matthew J. Rees et al.
BONE MARROW TRANSPLANTATION (2021)
Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Followup Analysis of the IFM 2009 Trial
Aurore Perrot et al.
BLOOD (2020)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens
Anthony Oyekunle et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma
Chong Chyn Chua et al.
BONE MARROW TRANSPLANTATION (2018)
Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
H. Quach et al.
INTERNAL MEDICINE JOURNAL (2015)
Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma
Sascha A. Tuchman et al.
JOURNAL OF CLINICAL APHERESIS (2015)
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
F. Cavallo et al.
LEUKEMIA (2011)
Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma
Uday Popat et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Shaji Kumar et al.
BLOOD (2009)
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
S. Giralt et al.
LEUKEMIA (2009)
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
Tomer Mark et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
S. Kumar et al.
LEUKEMIA (2007)
Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma
D. K. Hiwase et al.
CYTOTHERAPY (2007)
Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma
David Dingli et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone
KR Desikan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
